Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly To Begin Posting All Phase II-IV Trials To ClinicalTrials.gov

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is moving beyond the FDAMA requirements that only studies for serious or life-threatening diseases be included on the government-run database. Lilly will begin posting all new trials effective July 1; information for ongoing studies will be posted by Sept. 13.

You may also be interested in...



ClinicalTrials.gov Postings Should Include Studies For All Diseases – PhRMA

PhRMA revises earlier policy, which advised companies to post trials only for “serious and life-threatening” conditions, as mandated by FDAMA. Policy change comes as international trade associations adopt universal principles on clinical trial disclosure.

LillyTrials.Com Database Will Disclose Study Results For Marketed Products

Website will be expanded in the fourth quarter to include results of Lilly-sponsored clinical trials for marketed products, including Phase III data from failed studies of secondary indications.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel